Western Blot: LDL R Antibody [NBP1-06709] - Western Blot on HepG2 whole cell lysate.
Immunocytochemistry/ Immunofluorescence: LDL R Antibody [NBP1-06709] - LDL receptor antibody was tested in HepG2 cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight ...read more
Simple Western: LDL R Antibody [NBP1-06709] - Simple Western lane view shows a specific band for LDL R in 0.05 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa ...read more
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
PBS, 30% glycerol
0.1% Sodium Azide
Immunogen affinity purified
This LDL Receptor antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot, where bands are seen ~95 kDa and ~160 kDa representing the unglycosylated and glycosylated forms of the LDL receptor, respectively.In Simple Western only 10-15 uL of the recommended dilution is used per data point.
Human and Mouse. Predicted to react with monkey based on 100% sequence homology.
Alternate Names for LDL R Antibody
low density lipoprotein receptor
low-density lipoprotein receptor class A domain-containing protein 3
low-density lipoprotein receptor
LDL Receptor (low-density lipoprotein receptor or LDLR) is a key determinant of plasma cholesterol levels and as a ubiquitously expressed cell membrane glycoprotein, it binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells via endocytosis. LDLR is found distributed from plasma membrane to intracellular compartments, cell surface (in the presence of PCSK9) and also localizes to Golgi apparatus as well as early/late endosomes and lysosomes. VLDL, IDL, HDL, and chylomicron remnant are also recognized by LDLR at neutral pH. Receptor-ligand complexes undergo endocytosis via clathrin-coated pits and coated vehicle dispenses to endosomes with LRP6 and ARH (also known as LDLR adaptor protein), connecting LDLR family protein and the endocytic machinery; thereby, acidic condition activates dissociation of internalized ligands. Released ligand particles further travel to lysosomes wherein the ligand is degraded by enzyme, while the receptors recycle back to cell surface. After internalization, LDL particles trigger reduction in HMGCR expression to suppress cholesterol biosynthesis; enhancement of ACAT activity to reduce toxic free cholesterol, and suppression of LDLR synthesis to reduce LDL uptake via SREBPs. Genetic mutations impairing LDLR function results in a condition with extremely elevated serum LDL levels and early onset atherosclerosis known as familial hypercholesterolemia (FH).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.